Scleritis Market Report 2026

The scleritis market size has grown strongly in recent years. It will grow from $3.93 billion in 2025 to $4.28 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to rising prevalence of autoimmune disorders, use of corticosteroids in ocular therapy, availability of immunosuppressive agents, increasing number of ophthalmology clinics, growing awareness of ocular inflammatory diseases.

The scleritis market size is expected to see strong growth in the next few years. It will grow to $5.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to pipeline of biologic drugs for ocular inflammation, adoption of teleophthalmology platforms, development of targeted anti-inflammatory therapies, increased access to advanced imaging techniques, expansion of rare eye disease awareness programs. Major trends in the forecast period include expansion of biologic therapies for ocular inflammation, rising use of corticosteroids and immunosuppressive agents, growing adoption of combination therapy approaches, increased focus on early detection and diagnostic imaging, development of novel anti-inflammatory ophthalmic drugs.

The increasing prevalence of autoimmune diseases is expected to propel the growth of the scleritis market in the coming years. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues, perceiving them as foreign. The rise in autoimmune diseases is associated with genetic predispositions, environmental influences, lifestyle changes, and improved awareness, which contribute to better diagnosis. These conditions can lead to scleritis by triggering an inflammatory immune response that attacks the scleral tissue, resulting in pain and redness. For example, in August 2024, Public Health Scotland, a national organization based in Scotland, reported that in 2023, the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed multiple sclerosis patients. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the scleritis market.

Key companies in the scleritis market are focusing on developing advanced products, such as eye drops, to target underlying inflammation and offer practical, non-invasive treatment options. Eye drops are liquid formulations applied directly to the eyes to manage conditions such as irritation, dryness, inflammation, or infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, launched CYCLOTEARS eye drops in India and globally. This novel therapy for inflammatory eye disease uses proprietary SEDDS technology to enhance drug delivery and efficacy, representing a significant innovation in treating inflammation associated with dry eye disease, ocular myositis, and scleritis.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition provides Regeneron with an advanced delivery platform for ocular gene therapies, accelerating its progress toward clinical readiness. Additionally, it positions the company to improve therapeutic precision and drive innovation in eye care using Oxular’s proprietary technologies. Oxular Limited is a UK-based biotech company specializing in drug and device treatments for eye disorders, including scleritis.

Major companies operating in the scleritis market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Bayer AG, Novartis AG, Teva Pharmaceuticals USA Inc, Baxter International Inc, Boehringer Ingelheim, Regeneron Pharmaceuticals Inc, Fresenius Kabi USA LLC, Sun Pharmaceutical Industries Ltd, Perrigo Company, Horizon Therapeutics plc, Aurobindo Pharma Ltd, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Alvogen, Accord Healthcare, West Ward Pharmaceuticals, Jubilant Cadista Pharmaceuticals Inc, Mylan Pharmaceuticals Inc, Zydus Pharmaceuticals Inc.

North America was the largest region in the scleritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scleritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the scleritis market by increasing costs for imported biologic drugs, corticosteroids, and ophthalmic diagnostic equipment. Hospitals, ophthalmology clinics, and specialty pharmacies in regions such as Europe and Asia-Pacific are most affected due to reliance on imported therapies and devices. Tariffs have increased treatment costs and limited supply chains, they have also encouraged local production, regional sourcing, and innovation in cost-effective therapies, enhancing long-term market resilience.

The scleritis market research report is one of a series of new reports that provides scleritis market statistics, including scleritis industry global market size, regional shares, competitors with a scleritis market share, detailed scleritis market segments, market trends and opportunities, and any further data you may need to thrive in the scleritis industry. This scleritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Scleritis is an inflammation of the sclera, the white part of the eye. It is frequently associated with autoimmune disorders and can lead to severe eye pain, redness, and potential vision loss if left untreated. Proper diagnosis and treatment are essential to prevent long-term eye damage, and early intervention helps minimize the risk of complications such as vision loss.

The main types of scleritis include anterior scleritis, posterior scleritis, and others. Anterior scleritis involves inflammation of the front portion of the sclera, causing redness, pain, and swelling around the eyes. Treatment options include medications, surgery, and other therapies, which are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Management of the condition occurs in hospitals, specialty clinics, home healthcare settings, and other end-user environments.

The scleritis market consists of revenues earned by entities by providing services such as ultrasound, biologic therapies, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleritis market includes sales of ophthalmoscopes, nonsteroidal anti-inflammatory drugs, antibiotics, eye shields or patches, and cold or warm compress kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.